Amid DEG/EG contamination concerns, FDA issues guidance on testing high-risk drug components
Regulatory NewsJeff Craven
Chemistry, Manufacturing and Controls (CMC)North AmericaPharmaceuticalsProduct LifecycleQuality Assurance and ControlSupply Chain Management